Developer docs
API playgroundTry for free, no card

Search company profiles

Auxilium Biotechnologies

Full company profile

uuid0008ty5

Namestring
Auxilium Biotechnologies
Legal namestring
Auxilium Biotechnologies Inc.
Websiteurl
auxiliumbio.com
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Auxilium Biotechnologies is a clinical-stage biotechnology company developing regenerative medicine solutions centered on microgravity-based 3D bioprinting and implantable medical devices. The company operates two core product lines. The first is NeuroSpan Bridge™, described as the world's first biomimetic peripheral nerve repair device, which uses proprietary microchannel architecture to mimic the fascicular organization of peripheral nerves and align regenerating axons with their intended targets; it is currently in clinical trials under FDA IDE approval, with first patient enrolled in May 2025. The second is the AMP-1 Platform, a proprietary digital light processing (DLP) bioprinter engineered for microgravity environments that has demonstrated production of perfusable blood vessels in under one hour and eight implantable medical devices in two hours aboard the International Space Station.

The company's underlying technology exploits microgravity conditions to fabricate tissue structures and implantable devices with material properties and architectures not achievable under Earth gravity, including perfusable vascular systems and aligned nerve guidance conduits. Auxilium's go-to-market is bifurcated: NeuroSpan Bridge is positioned for enterprise field sales to healthcare providers treating traumatic peripheral nerve injury, while the AMP-1 platform is commercialized via strategic partnerships with commercial space station operators (Starlab Space, Vast) and research institutions (UC San Diego Sanford Stem Cell Institute, LambdaVision, BioOrbit) to deliver in-space biomanufacturing services for life science researchers. The company is privately held, headquartered in the Los Angeles area, founded in 2019, employs 11-50 people, and has raised approximately $7.2 million across disclosed rounds including an active $10 million SEC Form D offering filed in December 2025.

Customer segments are two-fold: peripheral nerve injury patients (primary use case for NeuroSpan Bridge) and life science research institutions seeking microgravity biomanufacturing capabilities (secondary use case for AMP-1 services). The company is pre-revenue, with all current income derived from equity financing and likely NASA-related grant funding following its 2022 NASA selection for a second-generation drug-delivery device proposal. Pricing for both product lines is not publicly disclosed, with commercial pricing contingent on future FDA approval for NeuroSpan Bridge and on service contract terms for AMP-1 biomanufacturing engagements.

Short descriptiontext

Auxilium Biotechnologies is a clinical-stage biotechnology company developing the NeuroSpan Bridge peripheral nerve repair device and the AMP-1 microgravity bioprinting platform, serving peripheral nerve injury patients and life science research institutions.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSan Diego, United States
HQ citystring
San Diego
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
peripheral nerve repair, bioprinting medical devices, microgravity biomanufacturing, regenerative medicine devices, tissue engineering implants
Industry3 codes
PRIMARYHLAHAEAD
Neurosurgical Implants & Cranial/CMF (Cranial Plates, Dural Repair, Shunts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAAAGAI
Neural & Spinal Cord Regeneration
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYIMAAAAAG
Bioprinting & Biofabrication Systems (Tissue/Cell Printing Hardware)
Industrials, Manufacturing & Construction/3D Printing/3D Printing Hardware (Printers & Systems)
NAICS code3 codes
  • Surgical Appliance and Supplies Manufacturing339113
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code2 codes
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
  • Surgical & Medical Instruments & Apparatus3841
Product category
Peripheral Nerve Repair Medical Devices
No data
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Implantable Medical Devices
TypeOne Time License
Description

Revenue from development and commercialization of implantable medical devices including the NeuroSpan Bridge nerve regeneration device. The company is currently in clinical trials with FDA IDE approval stage, suggesting a path to commercialize these products once regulatory approval is obtained.

businesswire.com
2Space-based Biomanufacturing Services
TypeProfessional Services
Description

Revenue from providing orbital 3D bioprinting and biofabrication capabilities aboard commercial space stations for research in regenerative medicine, implantable medical technologies, and tissue engineering. Partnerships with Starlab and Vast position the company to offer microgravity manufacturing services to life science researchers.

biospace.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Auxilium Biotechnologies develops and commercializes the NeuroSpan Bridge™, a biomimetic peripheral nerve repair device currently in FDA IDE clinical trials. The company also operates the AMP-1 Platform, a proprietary digital light processing 3D bioprinter designed for microgravity environments to fabricate implantable medical devices and perfusable vascular systems aboard the International Space Station and future commercial space stations.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Auxilium Biotechnologies is a biotechnology company developing bioprinting solutions and implantable medical devices for regenerative medicine. The company's portfolio consists of two core offerings: NeuroSpan Bridge™, the world's first biomimetic nerve repair device designed for peripheral nerve regeneration currently in clinical trials; and the AMP-1 Platform, a digital light processing 3D bioprinter capable of producing implantable medical devices and perfusable vascular systems in microgravity environments aboard the International Space Station and future commercial space stations.

Product and service3 records
1NeuroSpan Bridge™
CategoryImplantable Medical Devices
Description

World's first biomimetic nerve repair device that directs nerve regeneration across injury sites by aligning nerve bundles with their intended targets using microchannels that mimic the fascicular architecture of peripheral nerves. Currently in clinical trials for patients with traumatic peripheral nerve injuries.

2AMP-1 Platform
CategoryBiomanufacturing Platform
Description

Proprietary digital light processing 3D bioprinting platform designed for microgravity environments, supporting in-space biofabrication for regenerative medicine, implantable medical devices, and tissue engineering research. Demonstrated aboard the International Space Station and slated for future commercial space stations.

3Space-based Biomanufacturing Services
CategoryBiomanufacturing Services
Description

Microgravity 3D bioprinting and biofabrication services offered to life science researchers and institutions for regenerative medicine, implantable medical device development, tissue engineering, disease modeling, and drug development applications that cannot be replicated under Earth gravity.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
1Vast
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-24
Description

Memorandum of understanding signed with Vast to continue and expand biomedical research work currently conducted on the International Space Station after ISS retirement. Auxilium will leverage its 3D bioprinting capabilities for microgravity research aboard Vast's future commercial space station.

spacenews.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-06-24
Description

Part of Vast's partner network for microgravity research. Sanford Stem Cell Institute collaborates with Auxilium and other organizations to continue ISS biomedical research after station retirement.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-06-24
Description

Part of Vast's partner network for microgravity research. LambdaVision has completed nine ISS missions testing artificial retina production and raised $7 million last year.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-06-24
Description

Part of Vast's partner network for microgravity research. BioOrbit collaborates with other organizations including Auxilium to continue biomedical research after ISS retirement.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-10
Description

Partnership to provide orbital 3D bioprinting and biofabrication capabilities aboard Starlab's future commercial space station. Auxilium's AMP-1 bioprinter will support research in regenerative medicine, implantable medical devices, and tissue engineering. The collaboration aims to accelerate translation of experimental biology to manufacturable products in microgravity.

6NASA
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-04-15
Description

Selected by NASA for a proposal to develop a second-generation drug-delivery medical device to more effectively treat people who have sustained traumatic peripheral nerve injury. Demonstrated technology aboard ISS via NASA-sponsored missions.

auxiliumbio.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Organovo is a 3D bioprinting company developing functional human tissues for therapeutic and research applications. Comparable as a peer in 3D bioprinting for regenerative medicine, though Auxilium's microgravity focus and medical device orientation are distinguishing factors.

TypeBroad incumbent
Description

Integra LifeSciences manufactures a broad portfolio of neurosurgical implants, regenerative technologies, and surgical instruments including nerve repair products. Comparable as a diversified incumbent with overlapping nerve repair and neurosurgical device offerings.

TypeEmerging player
Description

Redwire is a space infrastructure company that has flown bioprinting and manufacturing payloads to the ISS and is developing in-space manufacturing capabilities. Comparable as a peer in commercial space-based biomanufacturing.

TypeBroad incumbent
Description

3D Systems is an established 3D printing hardware company with healthcare applications including bioprinting research and surgical planning. Comparable as a broad incumbent with overlapping bioprinting and medical device manufacturing capabilities.

5Aspect Biosystems
TypeEmerging player
Description

Aspect Biosystems develops microfluidic 3D bioprinting technology for creating functional human tissues with applications in drug discovery and regenerative medicine. Comparable as an emerging bioprinting peer with tissue engineering focus.

TypeBroad incumbent
Description

BICO owns CELLINK and other bioprinting and lab automation brands providing 3D bioprinters, bioinks, and tissue engineering consumables. Comparable as an established bioprinting hardware and consumables provider serving regenerative medicine researchers.

TypeDirect peer
Description

Axogen is the leading commercial player in peripheral nerve repair, offering nerve grafts (Avance), connectors, and caps. Directly comparable to Auxilium as the primary established company focused on surgical solutions for peripheral nerve injury.

TypeOthers
Description

LambdaVision is a partner of Auxilium using microgravity to produce artificial retinas aboard the ISS. Comparable as an adjacent microgravity biomanufacturing peer and existing partner in Vast's commercial space station research network.

TypeBroad incumbent
Description

Stryker is a major medical device company with neurotechnology, spine, and surgical implant portfolios. Comparable as a broad incumbent that could enter or expand in peripheral nerve repair and regenerative medicine.

TypeOthers
Description

BioOrbit is a partner in Vast's microgravity research network focused on space-based pharmaceutical manufacturing. Comparable as an adjacent microgravity biomanufacturing peer and existing ecosystem partner.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Auxilium Biotechnologies

Peripheral Nerve Repair Medical Devicesauxiliumbio.com

Auxilium Biotechnologies is a clinical-stage biotechnology company developing the NeuroSpan Bridge peripheral nerve repair device and the AMP-1 microgravity bioprinting platform, serving peripheral nerve injury patients and life science research institutions.

What Auxilium Biotechnologies does

Auxilium Biotechnologies is a clinical-stage biotechnology company developing regenerative medicine solutions centered on microgravity-based 3D bioprinting and implantable medical devices. The company operates two core product lines. The first is NeuroSpan Bridge™, described as the world's first biomimetic peripheral nerve repair device, which uses proprietary microchannel architecture to mimic the fascicular organization of peripheral nerves and align regenerating axons with their intended targets; it is currently in clinical trials under FDA IDE approval, with first patient enrolled in May 2025. The second is the AMP-1 Platform, a proprietary digital light processing (DLP) bioprinter engineered for microgravity environments that has demonstrated production of perfusable blood vessels in under one hour and eight implantable medical devices in two hours aboard the International Space Station.

The company's underlying technology exploits microgravity conditions to fabricate tissue structures and implantable devices with material properties and architectures not achievable under Earth gravity, including perfusable vascular systems and aligned nerve guidance conduits. Auxilium's go-to-market is bifurcated: NeuroSpan Bridge is positioned for enterprise field sales to healthcare providers treating traumatic peripheral nerve injury, while the AMP-1 platform is commercialized via strategic partnerships with commercial space station operators (Starlab Space, Vast) and research institutions (UC San Diego Sanford Stem Cell Institute, LambdaVision, BioOrbit) to deliver in-space biomanufacturing services for life science researchers. The company is privately held, headquartered in the Los Angeles area, founded in 2019, employs 11-50 people, and has raised approximately $7.2 million across disclosed rounds including an active $10 million SEC Form D offering filed in December 2025.

Customer segments are two-fold: peripheral nerve injury patients (primary use case for NeuroSpan Bridge) and life science research institutions seeking microgravity biomanufacturing capabilities (secondary use case for AMP-1 services). The company is pre-revenue, with all current income derived from equity financing and likely NASA-related grant funding following its 2022 NASA selection for a second-generation drug-delivery device proposal. Pricing for both product lines is not publicly disclosed, with commercial pricing contingent on future FDA approval for NeuroSpan Bridge and on service contract terms for AMP-1 biomanufacturing engagements.

Auxilium Biotechnologies firmographics

Firmographics
Name
Auxilium Biotechnologies
Legal name
Auxilium Biotechnologies Inc.
Website
https://auxiliumbio.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
1–10 employees
Short description
Auxilium Biotechnologies is a clinical-stage biotechnology company developing the NeuroSpan Bridge peripheral nerve repair device and the AMP-1 microgravity bioprinting platform, serving peripheral nerve injury patients and life science research institutions.
Ownership category
akta.pro rank

Auxilium Biotechnologies industry classification

Industry
Product category
Peripheral Nerve Repair Medical Devices
NAICS
Surgical Appliance and Supplies Manufacturing (339113), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHAEAD
Neurosurgical Implants & Cranial/CMF (Cranial Plates, Dural Repair, Shunts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAAAGAI
Neural & Spinal Cord Regeneration
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYIMAAAAAG
Bioprinting & Biofabrication Systems (Tissue/Cell Printing Hardware)
Industrials, Manufacturing & Construction/3D Printing/3D Printing Hardware (Printers & Systems)

Keywords

  • Peripheral nerve repair
  • Bioprinting medical devices
  • Microgravity biomanufacturing
  • Regenerative medicine devices
  • Tissue engineering implants

Where Auxilium Biotechnologies is headquartered

Location

Headquarters

HQ city
San Diego
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Auxilium Biotechnologies business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Implantable Medical Devices: Revenue from development and commercialization of implantable medical devices including the NeuroSpan Bridge nerve regeneration device. The company is currently in clinical trials with FDA IDE approval stage, suggesting a path to commercialize these products once regulatory approval is obtained.
  2. Space-based Biomanufacturing Services: Revenue from providing orbital 3D bioprinting and biofabrication capabilities aboard commercial space stations for research in regenerative medicine, implantable medical technologies, and tissue engineering. Partnerships with Starlab and Vast position the company to offer microgravity manufacturing services to life science researchers.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Auxilium Biotechnologies product offering

Product offering

Core offering

Auxilium Biotechnologies develops and commercializes the NeuroSpan Bridge™, a biomimetic peripheral nerve repair device currently in FDA IDE clinical trials. The company also operates the AMP-1 Platform, a proprietary digital light processing 3D bioprinter designed for microgravity environments to fabricate implantable medical devices and perfusable vascular systems aboard the International Space Station and future commercial space stations.

Product overview

Auxilium Biotechnologies is a biotechnology company developing bioprinting solutions and implantable medical devices for regenerative medicine. The company's portfolio consists of two core offerings: NeuroSpan Bridge™, the world's first biomimetic nerve repair device designed for peripheral nerve regeneration currently in clinical trials; and the AMP-1 Platform, a digital light processing 3D bioprinter capable of producing implantable medical devices and perfusable vascular systems in microgravity environments aboard the International Space Station and future commercial space stations.

Differentiator

Problem solved

Functional benefit

Products and services

  • NeuroSpan Bridge™ World's first biomimetic nerve repair device that directs nerve regeneration across injury sites by aligning nerve bundles with their intended targets using microchannels that mimic the fascicular architecture of peripheral nerves. Currently in clinical trials for patients with traumatic peripheral nerve injuries.
  • AMP-1 Platform Proprietary digital light processing 3D bioprinting platform designed for microgravity environments, supporting in-space biofabrication for regenerative medicine, implantable medical devices, and tissue engineering research. Demonstrated aboard the International Space Station and slated for future commercial space stations.
  • Space-based Biomanufacturing Services Microgravity 3D bioprinting and biofabrication services offered to life science researchers and institutions for regenerative medicine, implantable medical device development, tissue engineering, disease modeling, and drug development applications that cannot be replicated under Earth gravity.

Companies that use Auxilium Biotechnologies

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Auxilium Biotechnologies technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Auxilium Biotechnologies partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and minor.

  • VastcoreStrategic or Co-development Partner · 24 June 2026Memorandum of understanding signed with Vast to continue and expand biomedical research work currently conducted on the International Space Station after ISS retirement. Auxilium will leverage its 3D bioprinting capabilities for microgravity research aboard Vast's future commercial space station.
  • Sanford Stem Cell Institute at UC San DiegominorStrategic or Co-development Partner · 24 June 2026Part of Vast's partner network for microgravity research. Sanford Stem Cell Institute collaborates with Auxilium and other organizations to continue ISS biomedical research after station retirement.
  • LambdaVisionminorStrategic or Co-development Partner · 24 June 2026Part of Vast's partner network for microgravity research. LambdaVision has completed nine ISS missions testing artificial retina production and raised $7 million last year.
  • BioOrbitminorStrategic or Co-development Partner · 24 June 2026Part of Vast's partner network for microgravity research. BioOrbit collaborates with other organizations including Auxilium to continue biomedical research after ISS retirement.
  • Starlab Space LLCcoreStrategic or Co-development Partner · 10 February 2026Partnership to provide orbital 3D bioprinting and biofabrication capabilities aboard Starlab's future commercial space station. Auxilium's AMP-1 bioprinter will support research in regenerative medicine, implantable medical devices, and tissue engineering. The collaboration aims to accelerate translation of experimental biology to manufacturable products in microgravity.
  • NASAcoreStrategic or Co-development Partner · 15 April 2022Selected by NASA for a proposal to develop a second-generation drug-delivery medical device to more effectively treat people who have sustained traumatic peripheral nerve injury. Demonstrated technology aboard ISS via NASA-sponsored missions.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Auxilium Biotechnologies competitors and assessment

Company assessment

Direct peers

  • Organovo: Organovo is a 3D bioprinting company developing functional human tissues for therapeutic and research applications. Comparable as a peer in 3D bioprinting for regenerative medicine, though Auxilium's microgravity focus and medical device orientation are distinguishing factors.
  • Axogen: Axogen is the leading commercial player in peripheral nerve repair, offering nerve grafts (Avance), connectors, and caps. Directly comparable to Auxilium as the primary established company focused on surgical solutions for peripheral nerve injury.

Broad incumbents

  • Integra LifeSciences: Integra LifeSciences manufactures a broad portfolio of neurosurgical implants, regenerative technologies, and surgical instruments including nerve repair products. Comparable as a diversified incumbent with overlapping nerve repair and neurosurgical device offerings.
  • 3D Systems: 3D Systems is an established 3D printing hardware company with healthcare applications including bioprinting research and surgical planning. Comparable as a broad incumbent with overlapping bioprinting and medical device manufacturing capabilities.
  • BICO (CELLINK): BICO owns CELLINK and other bioprinting and lab automation brands providing 3D bioprinters, bioinks, and tissue engineering consumables. Comparable as an established bioprinting hardware and consumables provider serving regenerative medicine researchers.
  • Stryker: Stryker is a major medical device company with neurotechnology, spine, and surgical implant portfolios. Comparable as a broad incumbent that could enter or expand in peripheral nerve repair and regenerative medicine.

Emerging players

  • Redwire Corporation: Redwire is a space infrastructure company that has flown bioprinting and manufacturing payloads to the ISS and is developing in-space manufacturing capabilities. Comparable as a peer in commercial space-based biomanufacturing.
  • Aspect Biosystems: Aspect Biosystems develops microfluidic 3D bioprinting technology for creating functional human tissues with applications in drug discovery and regenerative medicine. Comparable as an emerging bioprinting peer with tissue engineering focus.

Others

  • LambdaVision: LambdaVision is a partner of Auxilium using microgravity to produce artificial retinas aboard the ISS. Comparable as an adjacent microgravity biomanufacturing peer and existing partner in Vast's commercial space station research network.
  • BioOrbit: BioOrbit is a partner in Vast's microgravity research network focused on space-based pharmaceutical manufacturing. Comparable as an adjacent microgravity biomanufacturing peer and existing ecosystem partner.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Auxilium Biotechnologies financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Auxilium Biotechnologies leadership team

Management profile

Number of profiles

Profiles1 record

Auxilium Biotechnologies funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Auxilium Biotechnologies M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Auxilium Biotechnologies

What does Auxilium Biotechnologies do?

Auxilium Biotechnologies develops and commercializes the NeuroSpan Bridge™, a biomimetic peripheral nerve repair device currently in FDA IDE clinical trials. The company also operates the AMP-1 Platform, a proprietary digital light processing 3D bioprinter designed for microgravity environments to fabricate implantable medical devices and perfusable vascular systems aboard the International Space Station and future commercial space stations.

Is Auxilium Biotechnologies a public or private company?

Auxilium Biotechnologies is a private company. It is classified as venture growth investor backed and is currently operating.

When was Auxilium Biotechnologies founded?

Auxilium Biotechnologies was founded in 2019. It employs 1 to 10 people.

Where is Auxilium Biotechnologies based?

Auxilium Biotechnologies is headquartered in San Diego, United States, in the North America region.

How does Auxilium Biotechnologies make money?

Two revenue lines are on record. Implantable Medical Devices are the primary driver. The others are space-based Biomanufacturing Services.

Who are Auxilium Biotechnologies's main competitors?

Direct peers on record are Organovo and Axogen. Broad incumbents are Integra LifeSciences, 3D Systems, BICO (CELLINK) and Stryker. Emerging players are Redwire Corporation and Aspect Biosystems. Others are LambdaVision and BioOrbit.

Does Auxilium Biotechnologies have an API?

No public API is recorded for Auxilium Biotechnologies.

What industry is Auxilium Biotechnologies in?

Auxilium Biotechnologies's product category is Peripheral Nerve Repair Medical Devices. Its primary akta.pro industry code is HLAHAEAD, Neurosurgical Implants & Cranial/CMF (Cranial Plates, Dural Repair, Shunts), with a secondary code of HLAAAGAI, Neural & Spinal Cord Regeneration. Its NAICS code is 339113 and its SIC code is 3842.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The Times of IndiaScientists create liver and kidney tissues in space for the first time in a microgravity environment: Expected to change the future of biological manufacturing | - The Times of IndiaIn June 2026, researchers successfully produced liver and kidney tissues aboard the International Space Station (ISS) for the first time in a microgravity environment, marking a milestone in biological manufacturing. The mission, conducted in partnership between Auxilium Biotechnologies and the Wake Forest Institute for Regenerative Medicine, also generated cartilage samples and 28 nerve repair implants, with materials returned to Earth via a SpaceX Dragon capsule on June 17. The microgravity conditions enabled more uniform cell distribution compared to Earth-bound methods, with scientists asserting this could reduce dependence on traditional manufacturing and open prospects for scalable production of complex medical tissues in space.Interesting EngineeringIn a first, scientists print kidney, liver tissues in space to beat gravityCalifornia-based Auxilium Biotechnologies successfully bioprinted kidney, liver, and cartilage tissues aboard the International Space Station using its AMP-1 orbital bioprinter, marking the first reported production of living kidney and liver tissues beyond Earth. The experiment demonstrated that microgravity helps overcome gravity-driven cell settling, allowing cells to distribute more evenly throughout printed tissues—an important step toward manufacturing complex biological structures in orbit. The returned samples are now being analyzed to assess how microgravity influenced tissue quality, though researchers caution that transplantable organs remain years away.DevdiscourseCelestial Wonders and Technological Triumphs: Exploring Space InnovationsThis article summarizes three distinct science news briefs: the discovery of an exoplanet surviving its star's death, a successful bioprinting experiment aboard the International Space Station, and China's testing of a new rocket retrieval system. The space station project involved Auxilium Biotechnologies and Wake Forest University creating lab-grown tissues, while China's test of the Long March 10B booster challenges U.S. dominance in reusable rocket technology.VoxelMattersAuxilium bioprints first kidney and liver tissues in space | VoxelMatters - The heart of additive manufacturingCalifornia-based Auxilium Biotechnologies has successfully bioprinted kidney and liver tissues aboard the International Space Station using its AMP-1 orbital bioprinter, marking the first time either tissue type has been manufactured in space. The bioprinted tissues were returned to Earth on June 17, 2026, as part of Mission AXLM-3 and will support research at the Wake Forest Institute for Regenerative Medicine. The company is developing its technology with Vast and Starlab for next-generation space stations and exploring applications for deep-space and lunar missions.FolhaTecidos de fígado e rim são bioimpressos no espaço - 09/07/2026 - Ciência - FolhaAuxilium Biotechnologies, a US biotech company based in San Diego, successfully bioprinted liver and kidney tissues containing human cells aboard the International Space Station for the first time, using a 3D bioprinter sent to space in 2024. The tissues, created in microgravity to overcome challenges of uneven cell distribution that occur under gravity on Earth, returned to Earth approximately two weeks before the July 9, 2026 article and are currently under analysis. The company, which originally developed this capability to improve nerve repair implants, has signed agreements with firms building commercial space stations to succeed the ISS and is beginning to navigate FDA regulatory pathways for space biomanufacturing.Channel NewsAsiaSpace station bioprinting experiment advances quest for lab-grown tissues, company saysSan Diego-based Auxilium Biotechnologies has successfully bioprinted human liver, kidney and cartilage tissues aboard the International Space Station for the first time, using microgravity to overcome the challenge of uneven cell distribution that plagues Earth-based tissue engineering. The printed structures, which have returned to Earth for analysis, represent a proof-of-concept for manufacturing medical tissues in orbit rather than functioning as transplantable organs. The company has signed agreements with firms developing commercial space stations to succeed the ISS, though medical products manufactured in space remain years from clinical use as regulatory frameworks are still taking shape.3D Printing IndustryAuxilium Biotechnologies Bioprints Kidney and Liver Tissue Aboard the ISSAuxilium Biotechnologies bioprinted kidney and liver tissue aboard the International Space Station during Mission AXLM-3 (SpaceX-34), marking the first time either tissue type was manufactured in orbit and the first time three distinct tissue types and 28 nerve repair implants were produced during a single spaceflight. The kidney and liver tissues were created using cells and tissue designs from the Wake Forest Institute for Regenerative Medicine, with Auxilium supplying the orbital manufacturing hardware. The company is working toward scalable orbital biomanufacturing through collaborations with Starlab Space and other commercial space station developers, positioning the technology for future commercial and deep-space applications.AOL.comAuxilium Biotechnologies Achieves Historic Space Bioprinting Milestone, Successfully Bioprinting Kidney and Liver Tissues in Orbit for the First TimeAuxilium Biotechnologies announced the successful bioprinting of kidney and liver tissues aboard the International Space Station on July 9, 2026, marking the first time either tissue type was manufactured in space. The mission (AXLM-3, returning on NASA's SpaceX CRS-34) also produced cartilage tissue and 28 nerve repair implants using Auxilium's AMP-1 orbital bioprinter, demonstrating the first scalable, multi-product biomanufacturing platform in space. The tissues were manufactured in support of research conducted by the Wake Forest Institute for Regenerative Medicine, which provided cells and tissue designs.Business Wire BlogAuxilium Biotechnologies Achieves Historic Space Bioprinting Milestone, Successfully Bioprinting Kidney and Liver Tissues in Orbit for the First TimeAuxilium Biotechnologies successfully bioprinted kidney, liver, and cartilage tissues aboard the International Space Station using its AMP-1 orbital bioprinter, marking the first-ever manufacturing of kidney and liver tissues in space. The mission, designated AXLM-3 and returning via SpaceX CRS-34 on June 17, 2026, also produced 28 nerve repair implants, demonstrating the first scalable, multi-product biomanufacturing platform capable of producing multiple tissue types and implantable medical products during a single spaceflight. The tissues were manufactured in support of research conducted by the Wake Forest Institute for Regenerative Medicine, which provided cells and tissue designs.DevdiscourseSpace station bioprinting experiment advances quest for lab-grown tissues, company saysSan Diego-based Auxilium Biotechnologies has successfully used its 3D bioprinter aboard the International Space Station to manufacture structures containing human liver, kidney, and cartilage cells for the first time, overcoming Earth's gravity limitations in controlling cell distribution within 3D structures. The liver and kidney tissues created on the ISS returned to Earth about two weeks ago and are being analyzed at Wake Forest University, which supplied the cells used in the experiments. While medical products manufactured in space remain years from clinical use, the work highlights growing commercial interest in space manufacturing as Auxilium has signed agreements with companies developing commercial space stations to succeed the ISS.